Sa1052 Fibrosis Progression in Nonalcoholic Fatty Liver Versus Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies

[1]  R. Loomba,et al.  Commentary: dissecting the PNPLA3 association with liver fat and stiffness, and interaction with diet , 2014, Alimentary pharmacology & therapeutics.

[2]  Rohit Loomba,et al.  The global NAFLD epidemic , 2013, Nature Reviews Gastroenterology &Hepatology.

[3]  A. Wree,et al.  From NAFLD to NASH to cirrhosis—new insights into disease mechanisms , 2013, Nature Reviews Gastroenterology &Hepatology.

[4]  B. Neuschwander‐Tetri,et al.  Clinical and histological determinants of nonalcoholic steatohepatitis and advanced fibrosis in elderly patients , 2013, Hepatology.

[5]  P. Bedossa,et al.  A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver. , 2013, Journal of hepatology.

[6]  G. Targher,et al.  Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis , 2013, Nature Reviews Gastroenterology &Hepatology.

[7]  Z. Kutalik,et al.  Genome-wide association study identifies variants associated with progression of liver fibrosis from HCV infection. , 2012, Gastroenterology.

[8]  M. Abraham,et al.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis , 2012, Hepatology.

[9]  K. Cusi,et al.  The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association , 2012, The American Journal of Gastroenterology.

[10]  S. Friedman,et al.  A polymorphism that delays fibrosis in hepatitis C promotes alternative splicing of AZIN1, reducing fibrogenesis , 2011, Hepatology.

[11]  J. Ioannidis,et al.  Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.

[12]  R. Green,et al.  Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. , 2011, Annals of hepatology.

[13]  D. O'Connor,et al.  Genetic covariance between gamma-glutamyl transpeptidase and fatty liver risk factors: role of beta2-adrenergic receptor genetic variation in twins. , 2010, Gastroenterology.

[14]  Scott Harmsen,et al.  Nonalcoholic Fatty Liver Disease Increases Risk of Death Among Patients With Diabetes: A Community-Based Cohort Study , 2010, The American Journal of Gastroenterology.

[15]  Vincent Wai-Sun Wong,et al.  Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.

[16]  B. Neuschwander‐Tetri,et al.  Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. , 2010, The New England journal of medicine.

[17]  P. Giral,et al.  Long‐term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial , 2009, Hepatology.

[18]  Greger Lindberg,et al.  Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.

[19]  E. Jackvony,et al.  Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis , 2010, Hepatology.

[20]  S. Sanderson,et al.  Betaine for nonalcoholic fatty liver disease: Results of a randomized placebo‐controlled trial , 2009, Hepatology.

[21]  S. Kaneko,et al.  Histological Course of Nonalcoholic Fatty Liver Disease in Japanese Patients , 2009, Diabetes Care.

[22]  S. Caldwell,et al.  Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. , 2009, Journal of hepatology.

[23]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement , 2009, BMJ : British Medical Journal.

[24]  S. Caldwell,et al.  Thiazolidinediones for the Treatment in NASH: Sustained Benefit After Drug Discontinuation? , 2009, Journal of clinical gastroenterology.

[25]  W. Coyle,et al.  The effect of metformin and standard therapy versus standard therapy alone in nondiabetic patients with insulin resistance and nonalcoholic steatohepatitis (NASH): a pilot trial , 2009, Therapeutic advances in gastroenterology.

[26]  Chunhong Bai,et al.  Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[27]  D. Kleiner,et al.  Placebo in nonalcoholic steatohepatitis: insight into natural history and implications for future clinical trials. , 2008, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[28]  G. Aithal,et al.  Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. , 2008, Gastroenterology.

[29]  B. Neuschwander‐Tetri,et al.  Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease , 2008, Gut.

[30]  T. Therneau,et al.  The NAFLD fibrosis score: A noninvasive system that identifies liver fibrosis in patients with NAFLD , 2007, Hepatology.

[31]  M. Holmqvist,et al.  Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.

[32]  Olivia T. Abar,et al.  Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. , 2006, Gastroenterology.

[33]  J. Sung,et al.  Histological progression of non‐alcoholic fatty liver disease in Chinese patients , 2005, Alimentary pharmacology & therapeutics.

[34]  E. Fassio,et al.  Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies , 2004, Hepatology.

[35]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[36]  R. N. Macsween,et al.  Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? , 2002, Journal of clinical pathology.

[37]  Z. Goodman,et al.  Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c. , 2001, Journal of hepatology.

[38]  M. Rugge,et al.  Progression of fibrosis in chronic hepatitis C in children , 2001 .

[39]  P. Giral,et al.  Liver fibrosis in overweight patients. , 2000, Gastroenterology.

[40]  B. Neuschwander‐Tetri,et al.  Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions , 1999, American Journal of Gastroenterology.

[41]  Z. Younossi,et al.  Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.

[42]  J P Vandenbroucke,et al.  Bias in meta-analysis detected by a simple, graphical test , 1998 .

[43]  M. Bennett,et al.  The natural history of nonalcoholic fatty liver: A follow‐up study , 1995, Hepatology.

[44]  P. Easterbrook,et al.  Publication bias in clinical research , 1991, The Lancet.

[45]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[46]  P. Tugwell,et al.  The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses , 2014 .

[47]  H. Schünemann,et al.  [GRADE guidelines: 7. Rating the quality of evidence - inconsistency]. , 2012, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.

[48]  S. Sanderson,et al.  The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. , 2005, Journal of hepatology.

[49]  J. Hoofnagle,et al.  Progression of fibrosis in chronic hepatitis C. , 2003, Gastroenterology.

[50]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.